Screener
Phathom Pharmaceuticals, Inc. PHAT EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Phathom Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 7:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324867
FAQ
- What is Phathom Pharmaceuticals, Inc.'s EPS (diluted)?
- Phathom Pharmaceuticals, Inc. (PHAT) reported EPS (diluted) of -$0.21 in Q2 2026.
- How has Phathom Pharmaceuticals, Inc.'s EPS (diluted) changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s EPS (diluted) increased by 80.0% year-over-year, from -$1.05 to -$0.21.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Phathom Pharmaceuticals, Inc.'s EPS (diluted) has grown at a -6.0% compound annual growth rate (CAGR), from -$3.89 to -$3.04.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Phathom Pharmaceuticals, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude